For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Metabolic Peptide
Eloralintide
A long-acting amylin analog designed as a selective agonist of the amylin 1 receptor (AMY1R), characterized in cell-based and rodent research.
Quantity
$278.99
Bundle & save
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2 business days
Overnight shipping available
Free shipment protection included
Eloralintide
1 × 13mg · $278.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
About Eloralintide
Structure and research context
Eloralintide (LY3841136) is a synthetic, long-acting amylin analogue designed as a selective agonist of the amylin 1 receptor (AMY1R), one of the heterodimeric amylin and calcitonin receptor complexes. It is one of a second generation of non-aggregating, long-acting amylin analogues whose design drew on structural understanding of these receptor complexes and on amylin structure-function relationships. The peptide has the formula C201H319N49O65S2 and a molar mass of about 4,526 g/mol.
Eloralintide in the research literature
In recombinant cell lines expressing individual amylin or calcitonin receptors, eloralintide preferentially activated AMY1R, at roughly 12-fold over the calcitonin receptor (CTR) and 11-fold over AMY3R, whereas at the rat receptors both AMY1R and AMY3R were activated more potently than CTR. This receptor profile distinguishes it from non-selective amylin and calcitonin receptor agonists such as cagrilintide.
It has also been studied in rodent models of energy balance, with pharmacokinetic profiling carried out in rats and monkeys.
Summarized from peer-reviewed literature for research context only; not a product claim. PubMed: 41109426 · 41747885
Eloralintide Certificate of Analysis
Third-party tested · Independent analytical lab
13mg
99.54%latest
| Tested | Measured | Purity |
|---|---|---|
| Jul 2026 | 13.99mg | 99.54% |
| Jun 2026 | 13.33mg | 99.82% |
| May 2026 | 13.78mg | 99.52% |
Frequently researched together
Commonly studied alongside Eloralintide.
Compound information
Technical specifications
Molecular profile
| Type | Selective amylin receptor agonist peptide |
| CAS number | 2883634-40-8 |
| Molecular weight | 4526 g/mol |
| Formula | C201H319N49O65S2 |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Eloralintide sources & references
Peer-reviewed literature, for research context
- Lancet (London, England)
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
2025·DOI: 10.1016/S0140-6736(25)02155-5·PMID: 41207310Billings LK, Hsia S, Bays H, Tidemann-Miller B, O'Hagan J, Tham LS
View source - Molecular metabolism
Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
2025·DOI: 10.1016/j.molmet.2025.102271·PMID: 41109426Briere DA, Qu H, Lansu K, He MM, Moyers JS, Coskun T
View source - Diabetes, obesity & metabolism
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
2026·DOI: 10.1111/dom.70439·PMID: 41559929Bhattachar S, Tham LS, Tidemann-Miller B, Ibriga H, Qu H, Briere DA
View source
More in Metabolic
Every Metabolic research compound in the catalog.
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.